Sanctuary Advisors LLC Buys Shares of 63,333 Avantor, Inc. $AVTR

Sanctuary Advisors LLC bought a new position in shares of Avantor, Inc. (NYSE:AVTR) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 63,333 shares of the company’s stock, valued at approximately $627,000.

A number of other large investors also recently modified their holdings of AVTR. Royal Bank of Canada raised its stake in Avantor by 104.3% during the first quarter. Royal Bank of Canada now owns 203,738 shares of the company’s stock worth $3,302,000 after acquiring an additional 104,022 shares during the period. Empowered Funds LLC lifted its holdings in shares of Avantor by 40.3% in the 1st quarter. Empowered Funds LLC now owns 17,659 shares of the company’s stock worth $286,000 after purchasing an additional 5,075 shares during the last quarter. Cetera Investment Advisers lifted its holdings in shares of Avantor by 40.2% in the 2nd quarter. Cetera Investment Advisers now owns 40,289 shares of the company’s stock worth $542,000 after purchasing an additional 11,543 shares during the last quarter. Quantbot Technologies LP acquired a new position in Avantor during the 2nd quarter valued at approximately $232,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in Avantor by 214.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 124,076 shares of the company’s stock valued at $1,670,000 after purchasing an additional 84,679 shares during the period. 95.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

AVTR has been the topic of several analyst reports. Stifel Nicolaus increased their target price on Avantor from $8.00 to $15.00 and gave the stock a “hold” rating in a research report on Thursday, July 30th. Wolfe Research upgraded shares of Avantor from a “strong sell” rating to a “hold” rating in a research report on Thursday, July 30th. Royal Bank Of Canada increased their price objective on shares of Avantor from $9.00 to $14.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $13.00 price objective on shares of Avantor in a research report on Thursday, July 30th. Finally, UBS Group set a $8.00 target price on shares of Avantor in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $12.00.

Avantor Trading Down 0.1%

Shares of AVTR stock opened at $14.60 on Friday. Avantor, Inc. has a 1 year low of $7.26 and a 1 year high of $15.93. The firm has a market capitalization of $9.87 billion, a PE ratio of -17.38, a price-to-earnings-growth ratio of 11.00 and a beta of 0.89. The stock has a fifty day moving average of $12.12 and a two-hundred day moving average of $9.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. The business had revenue of $1.69 billion for the quarter, compared to analysts’ expectations of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The company’s revenue was up .5% on a year-over-year basis. During the same period in the previous year, the business earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, research analysts expect that Avantor, Inc. will post 0.81 EPS for the current year.

About Avantor

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.